![]() |
|
| Delivering Innovative Renal and Vascular Therapies | |
|
Proteon Therapeutics, Inc is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The Company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). |
Headlines Proteon Therapeutics completes $12 million financing and hires CFO Proteon Therapeutics receives second issued U.S. patent broadly covering elastase vasodilation Proteon Therapeutics adds experienced research and drug development talent to its team EDC of Kansas City announces creation of “Kansas City Biotechnology Center” Proteon Therapeutics selects QSV Biologicals, Ltd for PRT-201 manufacturing Proteon Therapeutics hires veteran biotechnology executive as CEO Proteon Therapeutics, Inc. closes $19M in Series A financing |
| ©2008 Proteon Therapeutics Inc, All Rights Reserved | |